CN100502873C - 包含头孢菌素化合物的制剂 - Google Patents

包含头孢菌素化合物的制剂 Download PDF

Info

Publication number
CN100502873C
CN100502873C CNB028229258A CN02822925A CN100502873C CN 100502873 C CN100502873 C CN 100502873C CN B028229258 A CNB028229258 A CN B028229258A CN 02822925 A CN02822925 A CN 02822925A CN 100502873 C CN100502873 C CN 100502873C
Authority
CN
China
Prior art keywords
compound
formulations
composition
pharmaceutically acceptable
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028229258A
Other languages
English (en)
Chinese (zh)
Other versions
CN1604793A (zh
Inventor
R·N·金博尔
R·D·雷迪
E·Y·沙勒伊夫
S·E·布兰奇弗劳尔
B·S·布朗克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1604793A publication Critical patent/CN1604793A/zh
Application granted granted Critical
Publication of CN100502873C publication Critical patent/CN100502873C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNB028229258A 2001-11-30 2002-11-13 包含头孢菌素化合物的制剂 Expired - Lifetime CN100502873C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33853601P 2001-11-30 2001-11-30
US60/338,536 2001-11-30
US39893202P 2002-07-26 2002-07-26
US60/398,932 2002-07-26

Publications (2)

Publication Number Publication Date
CN1604793A CN1604793A (zh) 2005-04-06
CN100502873C true CN100502873C (zh) 2009-06-24

Family

ID=26991236

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028229258A Expired - Lifetime CN100502873C (zh) 2001-11-30 2002-11-13 包含头孢菌素化合物的制剂

Country Status (27)

Country Link
US (1) US7378408B2 (cg-RX-API-DMAC7.html)
EP (1) EP1448234B1 (cg-RX-API-DMAC7.html)
JP (1) JP4689959B2 (cg-RX-API-DMAC7.html)
KR (1) KR100621291B1 (cg-RX-API-DMAC7.html)
CN (1) CN100502873C (cg-RX-API-DMAC7.html)
AR (1) AR037595A1 (cg-RX-API-DMAC7.html)
AT (1) ATE406916T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002348986B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0214583B1 (cg-RX-API-DMAC7.html)
CA (1) CA2468708C (cg-RX-API-DMAC7.html)
CY (1) CY1108437T1 (cg-RX-API-DMAC7.html)
DE (1) DE60228749D1 (cg-RX-API-DMAC7.html)
DK (1) DK1448234T3 (cg-RX-API-DMAC7.html)
EA (1) EA008503B1 (cg-RX-API-DMAC7.html)
ES (1) ES2307800T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20040487A2 (cg-RX-API-DMAC7.html)
IL (2) IL161851A0 (cg-RX-API-DMAC7.html)
IS (1) IS7214A (cg-RX-API-DMAC7.html)
MA (1) MA27085A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04003724A (cg-RX-API-DMAC7.html)
NO (1) NO334818B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ532208A (cg-RX-API-DMAC7.html)
PL (1) PL212683B1 (cg-RX-API-DMAC7.html)
PT (1) PT1448234E (cg-RX-API-DMAC7.html)
TN (1) TNSN04097A1 (cg-RX-API-DMAC7.html)
TW (1) TWI248363B (cg-RX-API-DMAC7.html)
WO (1) WO2003045435A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021725A1 (it) 2002-08-01 2002-10-31 Zambon Spa Composizioni farmaceutiche ad attivita' antibiotica.
EP1740214B1 (en) * 2004-04-22 2007-10-03 Pfizer Products Incorporated Method of stabilizing disordered cefovecin sodium salt
EP1656930A1 (en) 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
NZ555076A (en) * 2004-12-17 2010-01-29 Venus Remedies Ltd Antibiotic combinations for providing total solution to the treatment of infections
CN101080221A (zh) * 2005-02-14 2007-11-28 维纳斯药业有限公司 抗药性细菌感染疾病的肠胃外综合治疗
ATE472996T1 (de) * 2005-10-29 2010-07-15 Intervet Int Bv Cefquinomzusammensetzungen und verfahren zu ihrer verwendung
US20080103121A1 (en) * 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
MX2010009628A (es) * 2008-03-04 2010-09-28 Elan Pharma Int Ltd Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731842B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8485861B2 (en) 2008-10-31 2013-07-16 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8858912B2 (en) 2008-10-31 2014-10-14 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8545856B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20140274991A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
ES3026983T3 (en) * 2013-03-15 2025-06-12 Merck Sharp & Dohme Llc Ceftolozane antibiotic compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
CA2991719C (en) * 2015-07-09 2023-07-04 Uniwell Laboratories Llc Pharmaceutical compositions
EP3348271B1 (en) 2015-09-07 2024-09-04 Mochida Pharmaceutical Co., Ltd. Freeze-dried alginic acid preparation
JP2020535212A (ja) 2017-09-27 2020-12-03 フェドラ・ファーマシューティカルズ・インコーポレイテッドＦｅｄｏｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ジアザビシクロオクタン誘導体の結晶型及びその生産プロセス
US10584123B2 (en) 2017-09-27 2020-03-10 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
JP7179058B2 (ja) * 2017-09-27 2022-11-28 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の剤形およびその生産プロセス
GB2575261B (en) 2018-07-02 2022-03-09 Norbrook Lab Ltd Intermediates in the synthesis of C3-substituted cephalosporins
CN109393004A (zh) * 2018-09-28 2019-03-01 上海锦立保鲜科技有限公司 一种利用冻品自由水升华实现真空解冻的方法
AU2022396967A1 (en) * 2021-11-26 2024-06-13 Astellas Pharma Inc. Indocyanine compound-containing solid pharmaceutical composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418058A (en) * 1980-06-23 1983-11-29 Shionogi & Co., Ltd. Protection of lyophilized betalactams from color formation
US4616083A (en) * 1983-08-22 1986-10-07 Shionogi & Co., Ltd. Stable antibacterial lyophilizates
CN1060469A (zh) * 1990-07-24 1992-04-22 比彻姆集团公司 头孢菌素衍生物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002748A (en) * 1976-01-19 1977-01-11 Eli Lilly And Company Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
SE8500273D0 (sv) * 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
US5138066A (en) * 1987-08-14 1992-08-11 Hoffmann-La Roche, Inc. Intermediates for cephalosporins with sulfur-containing oxyimino side chain
KR890012960A (ko) 1988-02-05 1989-09-20 매리 앤 터커 결정성 β-락탐 용매화물
CA2024587A1 (en) * 1989-09-05 1991-03-06 Bernard Ecanow Drug delivery compositions based on biological cells or components thereof and methods
US6020329A (en) * 1990-07-24 2000-02-01 Pzifer Inc. Cephaloporins and homologues, preparations and pharmaceutical compositions
US6001997A (en) * 1990-07-24 1999-12-14 Bateson; John Hargreaves Cephalosporins and homologues, preparations and pharmaceutical compositions
US5401842A (en) * 1992-09-08 1995-03-28 Bristol-Myers Squibb Company Injectable compositions of a cephalosporin dihydrate salt
EP0664117A1 (de) * 1994-01-25 1995-07-26 F. Hoffmann-La Roche Ag Liposomenlösungen
US5665760A (en) * 1995-09-18 1997-09-09 Sanofi Winthrop, Inc. Lyophilized thioxanthenone antitumor agents
KR100312622B1 (ko) * 1998-11-03 2002-02-28 김송배 생약을주성분으로한안정화된항암제조성물및그제조방법
JP2001199889A (ja) * 1999-11-11 2001-07-24 Takeda Chem Ind Ltd 縮合ピリダジン誘導体を含有してなる点鼻用剤
WO2001039836A1 (en) 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
GB0002835D0 (en) * 2000-02-09 2000-03-29 Melvin William T Drug resistance in cancer
GB0019124D0 (en) 2000-08-03 2000-09-27 Pfizer Novel process
CZ20031525A3 (cs) * 2000-12-04 2004-04-14 Pfizer Products Inc. Způsob přípravy 3-cyklickým etherem substituovaného cefalosporinu a meziprodukty pro tuto přípravu

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418058A (en) * 1980-06-23 1983-11-29 Shionogi & Co., Ltd. Protection of lyophilized betalactams from color formation
US4616083A (en) * 1983-08-22 1986-10-07 Shionogi & Co., Ltd. Stable antibacterial lyophilizates
CN1060469A (zh) * 1990-07-24 1992-04-22 比彻姆集团公司 头孢菌素衍生物的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Novel c-3 cyclic ether cephal osportins and their orallyabsorbed prodrug esters. BATESON J H ET AL.JOURNAL OF ANTIBIOTICS,JAPAN ANTIBIOTICS RESEARCH ASSOCIATION,,Vol.47 No.2. 1994
Novel c-3 cyclic ether cephal osportins and their orallyabsorbed prodrug esters. BATESON J H ET AL.JOURNAL OF ANTIBIOTICS,JAPAN ANTIBIOTICS RESEARCH ASSOCIATION,Vol.47 No.2. 1994 *

Also Published As

Publication number Publication date
AU2002348986B2 (en) 2008-04-03
TW200300351A (en) 2003-06-01
TNSN04097A1 (fr) 2006-06-01
DK1448234T3 (da) 2008-11-03
PT1448234E (pt) 2008-10-02
IS7214A (is) 2004-04-07
JP2005511642A (ja) 2005-04-28
ATE406916T1 (de) 2008-09-15
JP4689959B2 (ja) 2011-06-01
EP1448234B1 (en) 2008-09-03
HRP20040487A2 (en) 2004-10-31
US7378408B2 (en) 2008-05-27
NO334818B1 (no) 2014-06-02
CA2468708A1 (en) 2003-06-05
TWI248363B (en) 2006-02-01
AU2002348986A1 (en) 2003-06-10
NZ532208A (en) 2007-01-26
CA2468708C (en) 2008-08-19
EA200400489A1 (ru) 2004-10-28
PL370083A1 (en) 2005-05-16
HK1071292A1 (zh) 2005-07-15
IL161851A (en) 2011-11-30
DE60228749D1 (de) 2008-10-16
BR0214583A (pt) 2004-11-03
EA008503B1 (ru) 2007-06-29
ES2307800T3 (es) 2008-12-01
KR20040058345A (ko) 2004-07-03
PL212683B1 (pl) 2012-11-30
US20030186957A1 (en) 2003-10-02
CY1108437T1 (el) 2014-04-09
WO2003045435A1 (en) 2003-06-05
CN1604793A (zh) 2005-04-06
NO20042271L (no) 2004-07-22
MA27085A1 (fr) 2004-12-20
MXPA04003724A (es) 2005-04-08
EP1448234A1 (en) 2004-08-25
AR037595A1 (es) 2004-11-17
KR100621291B1 (ko) 2006-09-13
IL161851A0 (en) 2005-11-20
BRPI0214583B1 (pt) 2015-11-17

Similar Documents

Publication Publication Date Title
CN100502873C (zh) 包含头孢菌素化合物的制剂
JP7177314B2 (ja) セフトロザン抗生物質組成物
US11433115B2 (en) Glycopeptide antibiotics liquid formulations and methods and uses thereof
US20140274997A1 (en) Cephalosporin pharmaceutical compositions
US20250000935A1 (en) High-Stability Daptomycin Composition For Injection, And Preparation Method Therefor And Use Thereof
HK1071292B (en) Formulations comprising a cephalosporin compound
ZA200403933B (en) Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
NZ551403A (en) Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
US12409168B2 (en) Formulations of aminopenicillin and methods for solubilizing aminopenicillin
US20030149013A1 (en) Methods of treating bacterial infections in dogs and cats
WO2023165050A1 (zh) 一种稳定的酯肽类药物组合物
CN120548184A (zh) 新型眼科组合物
AU2002348985A1 (en) Methods of treating bacterial infections in dogs and cats
Bedenice et al. Bacterial Pneumonia in Horses: An Evidence-Based Guideline for Antimicrobial Therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1071292

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1071292

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: ZOETIS P CO., LTD.

Free format text: FORMER OWNER: PFIZER PRODUCTS INC.

Effective date: 20130618

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130618

Address after: American New Jersey

Patentee after: Shuo Teng P LLC

Address before: American Connecticut

Patentee before: Pfizer Products Inc.

ASS Succession or assignment of patent right

Owner name: SHUOTENG SERVICE LLC

Free format text: FORMER OWNER: ZOETIS P CO., LTD.

Effective date: 20150806

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150806

Address after: New jersey, USA

Patentee after: Zoetis Services LLC

Address before: American New Jersey

Patentee before: Shuo Teng P LLC

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20090624